ArticleBrain and behavior2021
Genistein acts as antidepressant agent against chronic mild stress-induced depression model of rats through augmentation of brain-derived neurotrophic factor.
Article in Brain and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Sex Differences in Oxidative Stress and Depression-Like Behavior Following Chronic Lead Exposure from Pregnancy to Adulthood.Biological trace element research · 2026Article
- Genistein mitigates estrogen deficiency and chronic stress-induced neuronal dysfunction via targeting ER-β, oxidative stress, inflammation, and apoptosis.Neuromolecular medicine · 2026Article
- Exploring the potential of polyphenols in major depression: from molecular function to clinical therapy.Frontiers in nutrition · 2026Review
- Genistein Exerts Neuroprotective Effects in an Ouabain-Induced Model of Bipolar Disorder: Behavioral and Molecular Insights.Neurochemical research · 2025Article
- Cannabichromene, a key non-psychotropic phytocannabinoid in treatment of major depressive disorder: in silico and in vivo explorations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Cannabigerol and Cannabinoid Receptors in Major Depressive Disorder: Network Pharmacology, Molecular Docking, andCurrent drug discovery technologies · 2025Article
- Review
- The gut microbiome in patients with Cushing's disease affects depression- and anxiety-like behavior in mice.Microbiome · 2024Article
- Role of Epigenetic Modulation in Neurodegenerative Diseases: Implications of Phytochemical Interventions.Antioxidants (Basel, Switzerland) · 2024Review
- Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.International journal of molecular sciences · 2024Article
- Mechanistic interplay of different mediators involved in mediating the anti-depressant effect of isoflavones.Metabolic brain disease · 2024Review
- Articulating the Pharmacological and Nanotechnological Aspects of Genistein: Current and Future Prospectives.Current pharmaceutical biotechnology · 2024Review
- Forced Swimming-Induced Depressive-like Behavior and Anxiety Are Reduced by Chlorpheniramine via Suppression of Oxidative and Inflammatory Mediators and Activating the Nrf2-BDNF Signaling Pathway.Current issues in molecular biology · 2023Article
- Roles of genistein in learning and memory during aging and neurological disorders.Biogerontology · 2023Review
- Hippocampal BMP signaling as a common pathway for antidepressant action.Cellular and molecular life sciences : CMLS · 2021Article
- Genistein acts as antidepressant agent against chronic mild stress-induced depression model of rats through augmentation of brain-derived neurotrophic factor.Brain and behavior · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the antidepression effects of genistein were investigated in rats induced with chronic mild stress. Animals were designated into the following groups: normal control, control, 10 mg, and 100 mg. The dose was given for 45 consecutive days via the oral route. Sucrose preference analysis, forced swim, and open field tests were performed, and serum cortisol and monoamine levels in brain tissue were determined. The mRNA and protein expression of brain-derived neurotrophic factor (BDNF) was also examined. Supplementation with genistein significantly increased the sucrose preference ratio, locomotor activity, and monoamines and decreased serum cortisol levels. The mRNA expression of BDNF in the brain tissue was substantially reduced by 0.73% in control rats. However, supplementation with genistein significantly increased BDNF mRNA expression (by 107% and 229.6% in groups 10 mg and 100 mg, respectively). Similarly, the protein expression of BDNF increased by 82.3% and 141.2% in groups 10 mg and 100 mg, respectively. Taken together, these results suggest that supplementation with genistein may be effective against depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.